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further elucidation of mechanisms. An essential component 
of this effort is the choice of compound training set that 
will be used to inform refinement and/or development of 
new model systems that allow prediction based on knowl-
edge of mechanisms, in a tiered fashion. In this review, we 
focus on the selection of MIP-DILI training compounds for 
mechanism-based evaluation of non-clinical prediction of 
DILI. The selected compounds address both hepatocellu-
lar and cholestatic DILI patterns in man, covering a broad 
range of pharmacologies and chemistries, and taking into 
account available data on potential DILI mechanisms (e.g. 
mitochondrial injury, reactive metabolites, biliary transport 
inhibition, and immune responses). Known mechanisms by 
which these compounds are believed to cause liver injury 
have been described, where many if not all drugs in this 
review appear to exhibit multiple toxicological mecha-
nisms. Thus, the training compounds selection offered a 
valuable tool to profile DILI mechanisms and to interrogate 
existing and novel in vitro systems for the prediction of 
human DILI.
Keywords Drug-induced liver injury (DILI) · MIP-DILI · 
Set of training compounds · Evidence-based selection · 
DILI mechanisms
Introduction
The appropriate selection of compounds for use in the 
evaluation of existing and novel model systems for the 
improved, and mechanism-based prediction of DILI in man 
requires special attention to overarching goals and strate-
gies of the research programme. It is important to evaluate 
evidence for mechanisms that actually occur in patients. In 
the case of the MIP-DILI consortium (www.mip-dili.eu), 
Abstract The current test systems employed by pharma-
ceutical industry are poorly predictive for drug-induced 
liver injury (DILI). The ‘MIP-DILI’ project addresses this 
situation by the development of innovative preclinical test 
systems which are both mechanism-based and of physi-
ological, pharmacological and pathological relevance to 
DILI in humans. An iterative, tiered approach with respect 
to test compounds, test systems, bioanalysis and systems 
analysis is adopted to evaluate existing models and develop 
new models that can provide validated test systems with 
respect to the prediction of specific forms of DILI and 
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the strategy of compound selection was to adopt a two-
tiered approach towards compound selection. The first tier 
was to adopt an evidence-based evaluation of drugs with 
perceivably known mechanism of toxicity and propensity 
to cause liver toxicity in the human population. The first 
tier of compounds, defined as training compounds, would 
serve to probe existing and novel in vitro and in vivo model 
systems for use in defining a panel of improved assays for 
use in pharmaceutical research and development. The sec-
ond tier, defined as test compounds, by contrast, comprises 
of legacy compounds from EFPIA Pharmaceutical compa-
nies previously known to cause liver injury in man or other 
(toxicology) species, but for which the mechanism(s) are 
poorly described. This paper describes the selection and 
compilation of known human DILI mechanisms on the set 
of training compounds identified for use in MIP-DILI.
For the evidence-based training compounds, the MIP-
DILI consortium aimed to use new knowledge gained 
during the project to further challenge existing and novel 
in vitro and in vivo systems for their value in both the 
understanding and prediction of DILI in man through com-
plementary experimental and computational modelling 
paradigms to generate quantitative outputs for use in pre-
dictive drug liver injury through use of a tiered and iterative 
strategy (Fig. 1).
Definition of training and test compounds
To support the concept of training and test compounds for 
use in the MIP-DILI consortium, definitions of each of 
these sets of compounds have been defined, as a consen-
sus agreement, by which to select compounds for use in the 
evaluation model systems.
Training compounds were defined as suitable ‘Drugs 
associated with biological processes which are presently 
thought to be relevant to the initiation or prevention of 
DILI in man, alongside an appropriate negative control’.
Test compounds (EFPIA legacy compounds): ‘Drugs 
which are associated with DILI in either preclinical or clin-
ical studies and could be potentially developed into a MIP-
DILI training compound’.
Mechanisms of drug-induced liver injury
The mechanisms by which most drugs cause liver injury 
are still poorly understood and subsequently hinder the 
detection of the hepatotoxic potential of drugs during pre-
clinical and early clinical development. For the most part, 
mechanisms are based on studies in single in vitro or ani-
mal model test systems without any direct read across to the 
clinical situation. An essential step in the selection and use 
of training compounds and test systems is a consideration of 
their pharmacological and physiological relevance to man.
Many drugs are lipophilic substances and require trans-
formation into metabolites by the phase I enzymes with 
subsequent conjugation by phase II enzymes to form 
water-soluble metabolites. While the majority of metabo-
lites form readily excreted bio-inactive metabolites, phase 
I and to a lesser extent phase II enzymes also can metabo-
lize drugs to electrophilic chemically reactive metabolites 
(CRMs) or unstable, reactive conjugates with the propen-
sity to covalently bind macromolecular molecules in cells; 
the long-term persistent formation of which are believed 
to cause cellular dysfunction and liver injury (Srivastava 
et al. 2010). Furthermore, it is now clear that the intracel-
lular concentration and persistence of a number of drugs 
is highly dependent on transporters which show variable 
expression. Knowledge of the disposition of training and 
test compounds in man is therefore vital for the interpreta-
tion of data from model systems. Coupled with the meta-
bolic capacity of the liver, pre-existing liver disease, age, 
genetic variation, oxygen supply and the intrinsic proper-
ties of drugs, all are considered to predispose the liver to 
cellular injury and death.
Fig. 1  Schematic representa-
tion of the MIP-DILI project 
strategy
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Recent advances in our understanding of cell death 
modalities, based on biochemical and cellular insights, 
reveal a host of subtle yet distinct pathways defining 
programmed cell death through apoptosis and necrosis 
pathways, as opposed to the classical view of regulated 
and non-regulated cell death (Vandenabeele et al. 2010; 
Papatriantafyllou 2012). Recent research suggests necro-
sis, in part, is mediated through programmed cell death 
(necroptosis) through activation by tumour necrosis fac-
tor alpha (TNFα), Fas ligand (FasL) and tumour necrosis 
factor (TNF)-related apoptosis-inducing ligand (TRAIL) 
by ligands also implicated in apoptosis (Degterev et al. 
2005). Necrotic cell death follows antioxidant consump-
tion and oxidation of cellular macromolecular proteins, in 
turn potentially affecting mitochondrial membrane perme-
ability, loss of mitochondrial membrane potential, decrease 
in ATP synthesis and disruption of Ca2+ homoeostasis. 
The mechanism of necroptosis is believed to be medi-
ated through reactive oxygen species (ROS) production in 
response to TNFα activation (Lin et al. 2004).
In contrast to necroptosis, programmed cell death also 
occurs through the more widely established activation of a 
family of cysteine proteases and caspases, to mediate apop-
totic cell death. Activation of caspases therefore occurs 
in response to agonistic death ligands, TNFα, FasL and 
TRIAL, and/or mitochondrial damage through the activa-
tion of pro-apoptotic BH-3 members of the BcL-2 family 
of ligands (Degterev et al. 2005; Christofferson and Yuan 
2010). While drug-mediated necroptotic events are emerg-
ing for hepatotoxic drugs (Han et al. 2007; Dunai et al. 
2012), it is widely accepted that many drugs cause liver 
injury through the caspase-dependent apoptotic pathways 
of cell death.
Apoptotic-inducing drugs are believed to alter the ener-
getic state of mitochondria thereby placing the role of mito-
chondria as central to drug-mediated apoptotic hepatocel-
lular injury and death. However, the previous classification 
of apoptotic and necroptotic pathways is perhaps now less 
clear for drug-related cell death, where roles for adenine 
nucleotide translocase and cyclophilin are implicated in 
membrane transition pore opening—a mechanism well rec-
ognized among several hepatotoxic drugs (Masubuchi et al. 
2002, 2005).
Non-parenchymal cells may also be targets in DILI 
with the activation of the immune system and subsequent 
idiosyncratic reactions in which human leucocyte antigen 
(HLA) genotypes are implicated in the aetiology of these 
types of liver injury. Consideration of these mechanisms of 
DILI forms the basis for the selection of a training set of 
compounds based on clinical pathology of liver injury, but 
where the actual mechanism of DILI remains to be better 
defined. Therefore, present day knowledge of mechanisms 
of liver injury forms the basis for selection of training 
compounds that are relevant to liver injury at the cellu-
lar level. While drugs are central to the mechanism-based 
selection of training compounds involved in liver injury, 
non-drugs such as rotenone may be valuable as reagents 
for use in demonstrating the relevance of in vitro models 
for the prediction of DILI in man, particularly with respect 
to understanding specific molecular initiating events and 
molecular pathways leading to DILI. It must be noted that 
DILI can be a multi-step and multicellular event and there-
fore drugs may be ‘complex reagents’.
In addition to the selection of compounds with known 
mechanisms affecting mitochondrial function, are those 
known to cause liver toxicities as a consequence of changes 
in the physiological function of the bile acid transport net-
work and steatosis. Among the many transporter proteins 
regulating the uptake and efflux of drugs and metabolites 
is the transport protein bile salt export pump (BSEP), the 
inhibition of which is implicated in the aetiology of several 
drug-induced liver toxicities.
The overarching goal of training compound selection is 
to develop a panel of best practice in vitro assays. How-
ever, the limitation of a mechanism-based strategy for the 
selection of training set of compounds relies on our present 
understanding of the mechanisms. The challenge, therefore, 
is to select training compounds based on our present mech-
anistic knowledge of cellular liver injury, yet contribute 
to our understanding and evaluation of existing and novel 
model systems for both the understanding and the predic-
tion of liver injury in man.
Acute and chronic forms of liver injury
The rationale of chronic versus acute dosing is to deline-
ate if acute dosing and repeated dosing leads to the same 
mechanism of toxicity (Ramachandran and Kakar 2009). 
For example, acute toxicity of CCl4 leads to centrilobular 
necrosis, but on cessation the liver fully recovers. By con-
trast, long-term exposure or repeated exposure leads to a 
centrilobular adaptation and finally to peripheral fibrosis. 
Overdose of APAP by contrast leads to necrosis with either 
fulminant liver failure or recovery and no fibrosis even fol-
lowing long-term repeated administration. Nitrofurantoin 
is another example that, on the one hand, can cause rare 
reversible acute liver injury and, on the other hand, more 
common chronic hepatitis with autoimmune-like features.
These examples of liver toxicants illustrate the a priori 
requirement to select training compounds on the basis of 
an understanding of the mechanism(s) of liver injury, such 
that these mechanisms are recapitulated in in vitro cellular-
based assays. Nevertheless, in the selection of training com-
pounds, the challenge is to understand these mechanisms as 
they relate to in vivo liver injury in human in both acute 
and chronic drug administration in patient populations.
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Compound selection criteria
Training compound selection was made by representa-
tives from both EFPIA companies and academia in the 
MIP-DILI consortium using data compiled by partners 
and assembled for evaluation in a purposed built Central 
data repository (CDR) for the compilation of background 
and foreground data. The goal was to select 10 training 
compounds positive for their propensity to cause DILI in 
man and, where possible, chemically matched negative 
compounds.
Criteria for the selection of training compound are sum-
marized in Table 1. The selection of training compounds 
was identified to broadly cover liver toxicity as defined by 
the perceived or known mechanisms of chemical insult and 
hepatocellular injury. The mechanisms of hepatocellular 
injury are broadly classified into five main areas namely 
(1) mitochondrial dysfunction, (2) chemically reactive 
metabolites and necrotic toxicity, (3) lysosomal dysfunc-
tion, phospholipidosis and steatosis, and (4) bile transport 
inhibition for the study of mechanisms of cellular injury in 
in vitro cellular-based models, and to include (5) adaptive 
or immune-mediated mechanisms believed to involve, but 
not restricted to, HLA phenotypes (Fig. 2).
Compound selection focused on marketed or for-
mally marketed drugs known to exhibit DILI in man, 
including both dose-dependent and idiosyncratic and/or 
dose-dependent toxicities. Of the 40 compounds nomi-
nated, 10 compounds were selected as training compounds 
for use in the initial phase of the research programme 
(Table 2). Acetaminophen (APAP), amiodarone, diclofenac, 
fialuridine and tolcapone were selected on evidence of 
mitochondrial dysfunction; APAP, diclofenac, nefazodone, 
tolcapone, and troglitazone on the formation of reactive 
metabolites; amiodarone, perhexiline, and troglitazone on 
causing lysosomal impairment and bosentan, diclofenac, 
nefazodone, perhexiline, and troglitazone as inhibitors of 
transport proteins (Table 2). Ximelagatran and flucloxacil-
lin were selected among a number of immune-mediated 
liver toxicities. Where possible, matched negative controls 
were identified, which in the case of tolcapone and trogl-
itazone were entacapone and pioglitazone, respectively. 
Chemical structures of MIP-DILI training compounds and 
negative controls are shown in Table 3.
Idiosyncratic toxicity and toxicity profiles 
of selected training compounds
Idiosyncratic toxicity
Drug-induced liver injury can be predictable and unpre-
dictable (‘idiosyncratic’). Predictable liver toxicity is 
dose dependent and, essentially, all patients will develop 
Table 1  Criteria for evidence-based selection of training compounds for the MIP-DILi project
DILI category Model hepatotoxins that selectively target specific pathways/systems in the hepatocyte
Model hepatotoxins that cause specific forms of DILI in preclinical model systems
Drugs that have a well-defined association (clinical phenotype, frequency, severity) with particular 
forms of DILI in man and in non-clinical models
Drugs that cause DILI in man but did not in available non-clinical test systems
Compounds that do not show liver damage either in pre-clinical tests or in man, but which  
are chemically related to drugs that are clearly associated with DILI, to act as negative controls
Mechanism known Molecular target
Reactive metabolites
CYP independent cell injury
Mitochondrial impairment
Inhibition of BSEP
Innate/adaptive immune activation
Other
DILI initiating primary event Evidence for primary event (in vitro/in vivo)
Evidence for mechanism (in vitro/in vivo)
Drug or metabolite involved
Dose—response
ADME data available? Characterization of drug exposure and metabolite profiles (Phase I–III)
DILI frequency in humans? Clinical evidence of liver injures reported
Human-specific DILI? Evidence of human only mechanism(s) of liability and liver injury
Human selective DILI? Sensitivity as it relates to in vivo or in vitro test systems
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liver injury if they receive a sufficiently high dose of the 
hepatotoxic drug. The toxicity of APAP remains one of 
the most extensively studied drugs known to cause dose-
dependent liver toxicity in humans and preclinical spe-
cies (Larson 2007). The term idiosyncratic means that the 
occurrence of DILI is a function of the individual. Such 
reactions may have an immunological basis, but this must 
not be assumed.
Alternatively, drugs known to form chemically reac-
tive metabolites (CRMs) can be associated with idiosyn-
cratic toxicity. These drugs which form CRMs provide 
evidence of a possible link between reactive metabolite 
formation and idiosyncratic liver toxicity—not necessar-
ily dose-dependent, occurring only in a small fraction of 
susceptible individuals and within the intended therapeutic 
range (Uetrecht 2000). Idiosyncratic adverse drug reactions 
(IDRs) associated with liver injury are reported in 50 % 
of the cases of acute liver failure (Abboud and Kaplowitz 
2007), but the frequency of IDRs is low accounting for 1 in 
10,000—1 in 100,000 patients. IDRs are often not identified 
until the drug reaches a large patient population. In Table 4, 
an overview is given of the selected training compounds 
involving the relevant processes and mechanisms in DILI.
Below the relevant mechanisms for DILI of the training 
compounds will be illustrated using representative train-
ing compounds. For details on the relevant processes and 
mechanisms involved in DILI of all training compound, 
reference is made to Table 5.
Fig. 2  Illustration of MIP-DILI 
relevant mechanisms of drug 
induced liver injury in man
Table 2  Panel of potential training compounds and the ultimate selected training compounds (green), four negative controls (white) and still to 
be decided (light green)
Mechanisms: 1 mitochondrial, 2 reactive metabolites, 3 lysosomal impairment, 4 BSEP inhibition, 5 immune-mediated
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Table 3  Chemical structures of MIP-DILI training compounds
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Compounds causing mitochondrial impairment 
(mechanism 1)
Mitochondrial dysfunction is a general term to include 
alterations of different metabolic pathways and damage 
to mitochondrial components (Fig. 3.1). Changes in mito-
chondrial homoeostasis can have a variety of deleterious 
consequences, such as oxidative stress, energy depletion, 
accumulation of triglycerides, and cell death. Mechanisms 
of mitochondrial dysfunction include membrane permea-
bilization, oxidative phosphorylation (OXPHOS) impair-
ment, fatty acid β-oxidation (FAO) inhibition and mtDNA 
depletion. Regarding steatosis, investigations suggest that 
besides mitochondrial dysfunction several other mecha-
nisms could be involved and they are discussed separately 
below using the training compounds as umbrella.
Fialuridine (mechanism 1)
Fialuridine was developed as an antiviral therapy for hepa-
titis B infection. In a phase II study, fialuridine caused 
severe toxicity: irreversible acute hepatic failure in 7 out 
of 15 patients, myopathy, myoglobinuria, severe lactic 
acidosis, and neuropathy after 9–13 weeks of treatment 
(McKenzie et al. 1995). Five out of 7 participants with 
severe hepatotoxicity died and two survived after liver 
transplantation liver transplant. Preclinical toxicology 
studies in mice, rats, dogs, and primates did not provide 
any indication that FIAU would be hepatotoxic in humans 
(Trials et al. 1995).
Histologic analysis of human liver tissue showed promi-
nent accumulation of microvesicular fat, with chronic 
active hepatitis and variable degrees of macrovesicular 
steatosis, but little hepatocellular necrosis, which is con-
sistent with the absence of substantial elevations in serum 
aminotransferase levels during treatment.(Kleiner et al. 
1997). Electron microscopy showed markedly swollen 
mitochondria, with loss of cristae, matrix dissolution, and 
scattered vesicular inclusions.
In studies of fialuridine in a human hepatoma cell line 
(Hep G2), the drug was incorporated into both nuclear and 
mitochondrial DNA, but at a much higher rate in the latter 
(Cui et al. 1995). Morphologic changes in mitochondria, 
microsteatosis, macrosteatosis, and increased lactic acid 
production were also observed. The integration of nucleo-
side analogues into nuclear DNA represents an alternative 
but potentially delayed pathway to cytotoxicity and cell 
apoptosis. Expression of a nucleoside transporter hENT1 in 
human (but not in mouse) mitochondria, which facilitates 
entry of fialuridine into mitochondria, may be responsible 
for the human-specific mitochondrial toxicity caused by 
fialuridine (Lee et al. 2006).
Recently, it has been shown that chimeric mice could be 
used as a model for fialuridine toxicity. The clinical fea-
tures, laboratory abnormalities, liver histology, and ultra-
structural changes observed were the same as in humans 
and these abnormalities developed in the regions of the 
livers that contained human hepatocytes but not in regions 
that contained mouse hepatocytes (Xu et al. 2014).
Reactive metabolites (mechanism 2)
Involvement of the liver in drug-related injury rests on 
the anatomical location of the liver and exposure to orally 
ingested drugs, physiology and metabolic capacity of 
the drug-metabolising enzymes. During drug absorp-
tion, some of the parent drug is metabolized to typically 
more hydrophilic entities, the metabolites of which are 
predominantly inert water-soluble metabolites, but can 
equally lead to the formation of chemically reactive spe-
cies, i.e. reactive metabolites (Fig. 3.2). And the process 
of drug bioactivation to CRMs is believed to be among 
the number of initiating events of many drug-related 
liver toxicities. The formation of CRMs can interact with 
Table 4  Overview of relevant 
processes and mechanism 
involved in DILI of training 
compounds
Training compound 1 2 3 4 5
Mitotoxicity CRM Lysosomal Biliary Immune
Fialuridine ✓
Acetaminophen ✓ ✓ ✓ (Innate)
Diclofenac ✓ ✓ ✓
Amiodarone ✓ ✓
Perhexiline ✓ ✓
Bosentan ✓
Tolcapone ✓ ✓ ✓
Nefazodone ✓ ✓
Troglitazone ✓ ✓ ✓ ✓
Ximelagatran ✓ (Adaptive)
Flucloxacillin ✓ (Adaptive)
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critical intracellular macromolecules leading to toxicity or 
further interaction with hepatoprotective entities such as 
glutathione (GSH). CRMs are typically electron deficient 
molecules (electrophiles) and if not detoxified these elec-
trophiles react with electron rich macromolecules such 
as proteins, nucleic acids and lipids with the potential to 
cause a change in biochemical function, or modified such 
that these modified proteins are processed by the immune 
antigen presenting cells. CRMs include quinone-imines, 
quinones, epoxides and reactive oxygen species and other 
free radicals. Most CRMs are short-lived leading to cel-
lular injury close to the site of formation, but less reactive 
species can diffuse to other surrounding cells and intracel-
lular organelles depending on concentration, rate of for-
mation of reactive metabolites and the nature of species 
formed, i.e. hard and soft electrophiles, such as quinones 
and quinine methides, respectively. Free radicals, by con-
trast, do not covalently interact with macromolecules, but 
pair with other free radicals forming covalent bonds with 
abstraction of hydrogen from neutral molecules to form a 
new free radical cation.
Acetaminophen (mechanisms 1, 2, 5)
The association of reactive metabolite formation and 
APAP toxicity is among the most documented example 
of drug liver injury (Bessems and Vermeulen 2001). At 
normal therapeutic doses, APAP is considered safe, but at 
high doses it is hepatotoxic and accounts for a large pro-
portion of drug-related morbidity in humans (Jaeschke 
2015). Registered annual percentage of acetaminophen-
related acute liver failure rose from 28 % in 1998 to 51 % 
in 2003 in multicentre US study (Larson et al. 2005). At 
therapeutic doses, APAP is conjugated to form the sul-
phate and glucuronides metabolites and accounts for 40 
and 20–40 % of the dose, respectively, in human. GSH 
conjugation accounts for less than 15 %. Because of cofac-
tor limitation, at high doses of APAP, oxidative metabo-
lism by CYP2E1, 1A2, 2D6, and 3A4 to the cytotoxic 
N-acetyl-p-aminoquinone-imine (NAPQI) becomes more 
important (James et al. 2003a; McGill and Jaeschke 2013). 
NAPQI can be reduced by NAD(P)H:quinone oxidore-
ductase 1 (NQO1) (Powis et al. 1987; Moffit et al. 2007), 
Bosentan
Diclofenac
Nefazodone
Troglitazone/Troglitazone sulphate
Prehexiline
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Fig. 3  Integrative picture of DILI-related mechanisms and MIP-DILI training compounds
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NAD(P)H:quinone oxidoreductase 2 (NQO2, unpublished) 
or GSH and be conjugated to GSH resulting in the for-
mation of 3-glutathionyl-paracetamol (APAP-SG) (Coles 
et al. 1988). Following depletion of GSH, NAPQI reacts 
increasingly with macromolecules causing subsequent 
hepatic necrosis. In certain individuals, APAP toxicity can 
arise with therapeutic doses (Vuppalanchi et al. 2007) and 
this ‘idiosyncratic’ response in liver injury may likely act 
as a contributing factor to the differences in the expression 
and activity of the phase I enzymes.
NAPQI interacts with protein thiols, by covalent binding 
and thiol-oxidation, including the plasma membrane Ca2+-
ATPase causing an increase in cytosolic Ca2+ concentra-
tions, changes to the actin skeletal structure and function 
and cell death by centrilobular hepatic necrosis. Covalent 
binding to critical cellular proteins has been postulated to 
be the main mechanism of toxicity (Hinson et al. 1995; 
Pumford and Halmes 1997) in animal species and man. 
However, the meta-isomer of APAP, N-acetyl-meta-ami-
nophenol (AMAP), appears to covalently bind with pro-
teins at levels similar to APAP, but without toxicity in mice 
or hamster, yet still it forms the analogous reactive metabo-
lite in rat and human precision-cut liver slices. It appears 
that AMAP covalently binds and inactivates CYP2E1 in 
mice, which contrasts the macromolecular covalent binding 
associated with NAPQI and ensuing necrosis located in the 
centrilobular region of the liver (Salminen et al. 1998; Hadi 
et al. 2013). While covalent binding has been attributed to 
the toxicity of NAPQI, mitochondrial dysfunction as a con-
sequence of APAP toxicity suggests a role of NAQPI-tar-
geted mitochondria through modification of proteins asso-
ciated with the electron transport chain, namely complex V, 
in addition to nitrated residues on Complex 1 in response to 
oxidative stress in mice (Qiu et al. 2001; Liu et al. 2009). 
More recently, APAP was shown to up-regulate the electron 
transport chain protein expression, possibly in response 
to oxidative stress and presence of unstable adducts with 
cysteinyl thiol groups (Stamper et al. 2011).
Studies also suggested a role of the innate immune sys-
tem in APAP toxicity (Jaeschke et al. 2012). Pro- and anti-
inflammatory cascades are simultaneously activated, and 
their balance plays a major role in determining the progres-
sion and severity of APAP-induced hepatotoxicity. A num-
ber of modulators of inflammatory responses have been 
described that can alter the severity of liver injury follow-
ing the initiation of toxicity. Up-regulation of TNFα and 
IL-1α occurs in the acetaminophen-treated mouse. How-
ever, the role of TNFα in APAP toxicity is somewhat con-
troversial (Boess et al. 1998; Simpson et al. 2000). Other 
pro-inflammatory cytokines: interleukin one beta (IL-1β) 
and interferon gamma (IFNγ) have also been examined 
in APAP toxicity (Blazka et al. 1995; Ishida et al. 2002; 
James et al. 2003b; Gardner et al. 2003). It was shown that 
depletion of interleukin (IL-6) resulted in increased sensi-
tivity to APAP (Masubuchi et al. 2003). Chemokines, e.g. 
macrophage inhibitor protein 2 (MIP-2), also play a role 
in acetaminophen-induced toxicity and are up-regulated in 
APAP toxicity (Lawson et al. 2000).
Intracellular signalling mechanisms also play a role in 
APAP toxicity: the c-Jun N-terminal kinases (JNKs), a sub-
family of the mitogen-activated protein (MAP) kinases, 
are activated by phosphorylation early in APAP toxic-
ity (Gunawan et al. 2006; Latchoumycandane et al. 2006; 
Henderson et al. 2007) and DNA fragmentation is another 
mechanism that has been implicated in acetaminophen-
induced hepatotoxicity (Salas and Corcoran 1997). Subse-
quently, it was reported that endonuclease G was important 
in the acetaminophen-induced nuclear fragmentation (Bajt 
et al. 2006).
As described, the hepatotoxicity of APAP appears to 
occur by a complex mechanistic sequence. Associated 
with these essential events, there appears to be a number 
of modulators of inflammatory responses that can alter the 
severity of liver injury. The threshold and susceptibility 
to APAP hepatotoxicity is determined by the interplay of 
injury promoting and inhibiting events downstream of the 
initial production of toxic metabolite where environmental 
and genetic control may be of critical importance in deter-
mining susceptibility to APAP hepatotoxicity.
Diclofenac (mechanisms 1, 2, 4)
Therapeutic use of diclofenac (DF) is associated with rare 
but sometimes fatal hepatotoxicity with a characteristic 
delayed onset of symptoms and poor dose–response rela-
tionship. Elevated levels of liver enzymes develop in about 
15 % of patients that are regularly taking diclofenac and a 
threefold rise in transaminase levels has been reported in 
5 % (Banks et al. 1995). Clinically relevant hepatotoxic-
ity leading to hospital referral occurs in 6.3 per 100,000 
diclofenac users (de Abajo et al. 2004).
In contrast to APAP, diclofenac requires initial hydroxy-
lation by CYP2C9 and CYP3A4, or peroxidase-mediated 
oxidation to form different quinone-imine reactive metab-
olites from 4′ and 5-hydroxydiclofenac, which in turn can 
form adducts with macromolecular proteins or form con-
jugates with GSH (Tang et al. 1999; Madsen et al. 2008b). 
The parent diclofenac also forms a reactive acyl-glucuro-
nide metabolite with the formation of covalent modifica-
tion of cellular proteins and the covalent binding to liver 
proteins in rats, which is linked to the activity of a hepatic 
canalicular transport protein, Mrp2 (Tang 2003). The acyl-
glucuronide and the quinone-imines of diclofenac, derived 
from metabolic activation of diclofenac, are both implicated 
in covalent modification of cellular proteins with the dis-
ruption of critical cellular functions and/or immunological 
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response in susceptible patients (Shen et al. 1999; Kenny 
et al. 2004). Besides GSH conjugation, it has been shown 
that quinone-imines of 4′ and 5-hydroxydiclofenac can 
be detoxified by reduction by polymorphic NQO1 as well 
(Vredenburg et al. 2014).
Besides distinct chemically reactive metabolites, other 
diclofenac-related hazards have been identified and have 
been studied. These include oxidative stress generation 
based on peroxidase-catalysed production of radicals, 
which in turn can oxidize GSH and NAD(P)H, while 
molecular oxygen may be reduced and activated or the 
radicals undergo redox cycling (Galati et al. 2002). Also, 
mitochondria are a major subcellular target for diclofenac. 
Diclofenac disturbs in vitro liver mitochondrial function at 
multiple levels, including the phosphorylating system and 
mitochondrial permeability transition pore, being associ-
ated with increased oxidative stress and apoptotic signal-
ling (Masubuchi et al. 2002; Gómez-Lechón et al. 2003). 
In high concentrations, diclofenac causes rapid and concen-
tration-dependent ATP depletion. Diclofenac decreases the 
mitochondrial transmembrane potential by direct effects on 
the mitochondrial inner membrane, uncoupling of respira-
tion by proton shuttling or opening of the mitochondrial 
membrane permeability transition pore. In HepG2 cells, 
TNFα enhances hepatocyte injury caused by diclofenac 
(Fredriksson et al. 2011). Diclofenac-mediated stress sig-
nalling suppressed TNFα-induced survival signalling 
routes and sensitizes cells to apoptosis. However, a striking 
but somewhat sobering conclusion is that we still do not 
understand the real reasons for the individual susceptibility 
in patients.
Lysosomal impairment (steatosis and phospholipidosis; 
mechanism 3)
Microvesicular steatosis or microsteatosis is a form of liver 
toxicity which is associated with liver failure, pronounced 
hypoglycaemia and encephalopathy in patients (Farrell 
2002; Stravitz and Sanyal 2003). Liver pathology reveals 
the presence of numerous cytoplasmic lipid droplets, vis-
ible by staining with oil red O. Liver triglycerides can 
accumulate as vacuolar lipid bodies within the hepatocyte 
by a number of drugs (Farrell 2002; Labbe et al. 2008) and 
frequently referred to as non-alcoholic fatty liver (NASH), 
which is most frequently observed in obese, diabetic 
patients and related disorders. Progression from fibrosis 
to cirrhosis can occur rapidly. Drugs responsible for this 
hepatic lesion can also induce a mixed form of fat accu-
mulation with macrovacuolar steatosis and microvesicular 
steatosis occurring in anatomically adjacent hepatocytes, 
the formation of which may depend on proteins such as 
perilipin and adipophilin associated with lipids and pos-
sible presence of free fatty acids (Fromenty and Pessayre 
1995). The mechanisms associated with macrovacuolar and 
microvesicular steatosis remain to be confirmed, but steato-
sis arises from either an increased availability of free fatty 
acids to the liver and stimulation of de novo hepatic lipo-
genesis (Begriche et al. 2006; Moreau et al. 2009). Drugs 
known to cause steatosis can be broadly divided into those 
with steatosis and steatohepatitis with well-characterized 
mechanisms of hepatotoxicity, for example, amiodarone, 
fialuridine and perhexiline. Other drugs form less well-
defined mechanisms include latent forms of NASH, such as 
tamoxifen, and episodic cases of steatosis and steatohepa-
tosis, such as carbamazepine.
Cationic amphiphilic compounds comprise a lipophilic 
moiety and amine group, the latter of which becomes pro-
tonated as the drug crosses from the cytosol into the acidic 
milieu of lysosomes or crosses the outer membrane of the 
mitochondrion into the acidic inter-membrane space where 
the uncharged drug is subsequently protonated and unable 
to pass back across the membrane as the positively charge 
species. As a consequence of the charge distribution, 
drug accumulates in lysosomes as the positively charged 
drug forming noncovalent complexes with phospholipids 
(Fig. 3.3). As the drug-phospholipid complexes are not 
degraded, these complexes progressively accumulate in the 
form of myelin structures of enlarged lysosomal bodies. 
The clinical pathology of cationic amphiphilic accumula-
tion of drugs, as phospholipids, leads to the common occur-
rence of phospholipidosis in patients, yet the clinical conse-
quences of which appears with limited clinical symptoms. 
By contrast, cationic amphiphilic drugs crossing the outer 
mitochondrial membrane are protonated and through the 
electrochemical gradient pass to the inner mitochondrial 
matrix where these drugs accumulate targeting processes 
of mitochondrial function linked with e-transport chain and 
fatty acid metabolism.
Amiodarone (mechanisms 1, 3)
Amiodarone is a cationic amphiphilic lipophilic compound 
(Atiq et al. 2009) with the propensity to accumulate in the 
lipid-rich environment of organelles affecting both mito-
chondrial and lysosomal function and thus causes liver 
damage by a number of mechanisms: microvesicular stea-
tosis, concomitant macrovacuolar steatosis and steatohepa-
titis, and phospholipidosis. Elevated blood levels of liver 
enzymes have been recorded in 14–82 % of patients (Lewis 
et al. 1989).
As a consequence of the charge distribution from cytosol 
to the acidic milieu, amiodarone accumulates and inhibits 
phospholipase activity through one of two mechanisms: 
firstly, by formation of noncovalent complexes with phos-
pholipids in lysosomes and as the drug-phospholipid com-
plexes are not degraded, these complexes progressively 
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accumulate as described above (Pirovino et al. 1988), 
leading to phospholipidosis; secondly, amiodarone and 
its metabolites (e.g. N-desmethylamiodarone) accumulate 
in lysosomes of parenchymal, bile duct epithelium and 
kupffer cells with inhibition of the metabolism of lysoso-
mal lipids by phospholipases A1 and A2 leading to phos-
pholipidosis (Heath et al. 1985).
Phospholipidosis can occur within 2 months of starting 
amiodarone therapy (Capron-Chivrac et al. 1985; Rigas 
et al. 1986) and occurs in a higher percentage of patients 
receiving amiodarone than the incidence of hepatocellular 
damage (Atiq et al. 2009), suggesting amiodarone-induced 
phospholipidosis may only have a contributory role 
towards the more serious consequences of amiodarone-
induced hepatotoxicity and cirrhosis. Therefore, diagnosis 
of phospholipidosis in patients serves as a biomarker for 
the accumulation of amiodarone (Atiq et al. 2009) rather 
than as a biomarker for the more serious forms of amiodar-
one hepatotoxicity.
With formation of enlarged lysosomal bodies, the 
release of proteolytic enzymes from aberrant lysosomes is 
a mechanism likely attributed to amiodarone-induced liver 
damage (Guigui et al. 1988; Yagupsky et al. 1985; Lewis 
et al. 1990). With the seepage of proteolytic enzymes over 
prolonged periods, the proteolytic enzymes may in turn 
contribute to the elevation of aminotransferases leading to 
hepatic necrosis, fibrosis, and cirrhosis of the liver.
Amiodarone-induced inhibition of cellular respiration 
is another possible pathogenic mechanism for amiodar-
one-induced liver damage. Impairment of mitochondrial 
β-oxidation and uncoupling of oxidative phosphorylation 
leads to the formation of reactive oxygen species, which in 
turn has a role in the development of amiodarone-induced 
cirrhosis (Fromenty et al. 1990a, b).
In addition to the usual pathologic findings of cirrhosis, 
leucocytic infiltrate and high Mallory’s hyaline (Mallory’s 
bodies) are suggestive of amiodarone-induced cirrhosis 
together with the presence of phospholipid-rich lamellar 
lysosomal inclusion bodies (Lewis et al. 1990).
Although amiodarone hepatotoxicity is serious and 
potentially fatal, such effects are rare. Asymptomatic 
liver enzyme elevation occurs in 25 % of the popula-
tion treated with amiodarone (Lewis et al. 1989) and is 
usually reversible upon discontinuation of therapy (Pol-
lak 2010). Symptomatic hepatic dysfunction occurs in 
less than 1 % of the population treated with amiodarone. 
Besides chronic liver injury which includes steatosis 
(macro and microvesicular steatosis) and cirrhosis due 
to prolonged amiodarone use, acute hepatic side effects 
(idiosyncratic reaction may be involved in pathogenesis) 
from amiodarone intravenous loading dose have been 
reported (Rätz Bravo et al. 2005).
Perhexiline (mechanisms 3, 4)
Perhexiline is an anti-anginal drug, which despite its effi-
cacy diminished in its use due to a small number of cases 
of severe hepatotoxicity and neurotoxicity. Perhexiline is 
mainly metabolized by the polymorphic CYP2D6 in the 
liver, and these side effects were related to high plasma 
concentrations with standard doses in poorly metabolizing 
patients (Wright et al. 1973; Shah et al. 1982).
At high concentrations, protonated perhexiline rap-
idly accumulates in mitochondria along the mitochondrial 
membrane potential as an amphiphilic (or amphipathic) 
molecule. A multitude of effects on mitochondria have 
been reported, including the uncoupling of mitochondrial 
oxidative phosphorylation, inhibition of complexes I and II, 
and decreased ATP formation. The most evident effect was 
fatty acid metabolism inhibition (Ashrafian et al. 2007). 
Most importantly, characteristic lamellar lysosomal inclu-
sion bodies representing phospholipidosis as well as tri-
glyceride and fatty acid accumulation were identified.
Cholestasis, inhibition of biliary efflux and BSEP 
(mechanism 4)
Cholestatic and mixed cholestatic and hepatocellular injury 
are forms of severe DILI in man. Recent evidence of drugs 
secreted into the bile suggests these drugs are primary can-
didates inducing cholestatic liver disease in patients, but 
do not induce hepatotoxicity in rats. The flow of bile is 
highly regulated through several basolateral and canalicu-
lar transport proteins such as Na+-dependent taurocholate 
transport protein, BSEP and a series of multi-drug resist-
ance associated proteins. Among these transport proteins, 
BSEP is believed to play a pivotal role for DILI and inhibi-
tion of this transport protein leading to cholestatic injury. 
Bile acid accumulation in hepatocytes as a consequence 
of BSEP inhibition is proposed as a mechanism for the 
hepatotoxicity of several drugs including cyclosporine, tro-
glitazone and bosentan (Fig. 3.4). Of those drugs causing 
cholestasis in patients, several do not cause a similar pat-
tern of cholestatic injury in the rat, but nevertheless inhibit 
Bsep with reported elevations in the levels of serum bile 
acids. Explanations for the lack of toxicity in the rat stem 
from either the inhibition of uptake transport proteins and/
or differences in the inhibitory potential of human BSEP 
and rat Bsep. Alternative explanations for the lack of hepa-
totoxicity in the rat are provided by the complement of 
bile acids comprising the bile acid pool in the liver—rat 
bile acid composition being more hydrophilic and there-
fore less toxic than the composition of human bile acids. 
Nevertheless, the overall interplay and mechanisms of 
drug-induced cholestasis remain poorly defined. Among 
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several studies on the role of BSEP hepatocellular injury, 
two substantive studies link hepatotoxicity to BSEP inhibi-
tion. Of those drugs evaluated, 75 % of drugs exhibit IC50 
greater than 133 µM and therefore were viewed negative. 
By contrast, 16 % showed greater inhibition of BSEP with 
IC50 ≤25 µM (Morgan et al. 2010) and in a further study, 
17 of 85 drugs with an IC50 <100 µM and Cmax,u >2 nM 
are known to cause DILI in man (Dawson et al. 2012). 
Both these studies, and others, conclude that BSEP inhibi-
tion plays a role in cholestatic injury in patients.
Bosentan (mechanism 4)
The proposed mechanism of bosentan-induced choles-
tasis is presently thought to be mediated, at least in part, 
by inhibition of BSEP activity and is among one of the 
more extensively investigated drugs to inhibit BSEP. The 
mechanism of bosentan-induced liver injury in patients is 
believed, at least in part, to be mediated inhibition of the 
canalicular bile transport protein BSEP with accumula-
tion of bile acids as the prevailing mechanism in the aeti-
ology of bosentan-induced liver injury in patients (Fat-
tinger 2001). Consistent with this, proposed mechanism 
is the observed inhibition of BSEP in vitro models and the 
incidence of dose-related liver injury in patients, which is 
reversible with reduction of daily dose (Noé et al. 2002; 
Mano et al. 2007). The inhibition of BSEP is further sup-
ported by clinical observations demonstrating the increase 
in serum bile acids and the toxicity of bosentan is more 
commonly observed in patients co-treated with glyburide, 
a known inhibitor of BSEP (Stieger et al. 2000). Bosentan 
is mainly eliminated by hepatic metabolism and subsequent 
biliary excretions of three metabolites formed by CYP 2C9 
and 3A4 (Pichler et al. 1988) with no evidence of reactive 
metabolite formation.
The intravenous administration of bosentan to rats 
increases the level of serum bile acids suggesting the rat 
as a possible model for the study of BSEP inhibition and 
hepatotoxicity in man (Fattinger 2001). However, treatment 
of rats with bosentan does not cause liver injury where a 
basolateral compensatory role of Ntcp, expressed more 
than human NTCP, contributes to the sinusoidal transport 
of bile acid elimination and a reduction in intracellular 
accumulation of bile acids in the liver of rats (Hagenbuch 
and Meier 1994). In the rat, bosentan is a more potent 
inhibitor of Ntcp than the human NTCP in suspensions 
of hepatocytes and in vesicles expressing Ntcp and NTCP 
proteins with mechanisms of non-competitive and competi-
tive inhibition, respectively (Leslie et al. 2007).
Mild forms of bosentan-associated liver toxicity occurs 
in approximately 10 % in patients within 6 months, but 
less frequently serious liver toxicities are reported and are 
often associated with co-morbidities (Eriksson et al. 2011). 
The idiosyncratic nature of bosentan; delay of onset, role 
of comorbidities and variable extent of the mild to severe 
forms of liver toxicities and perceived mechanism of 
bosentan-induced liver toxicity was selected as the a priori 
training compound for inclusion for the study of BSEP and 
drug transport studies.
Nefazodone, troglitazone, diclofenac, tolcapone and 
perhexiline are among a number of other drugs selected as 
training compounds with implications for the inhibition of 
bile transport proteins.
Tolcapone (mechanisms 2, 4)
Tolcapone is a selective and reversible inhibitor of the 
enzyme catechol-O-methyl transferase (COMT) and is used 
as an effective adjunct to levodopa/carbidopa in the treat-
ment of Parkinson’s disease. However, tolcapone is under 
strict regulations on liver enzyme monitoring due to the 
hepatic failures that appeared, three of them with fatal out-
come. In 1998, tolcapone was actually withdrawn from the 
European Union (EU) and Canadian markets due to liver 
problems, but it is again reintroduced to EU. Liver function 
elevations above the upper limit of normal (ULN) occurred 
in 20.2 and 27.5 % of patients in the placebo and active 
treatment groups, respectively; increases ≥3 times the ULN 
occurred in 1.2 and 1.7 % of patients (Lees et al. 2007).
The mechanism of hepatotoxicity introduced by tol-
capone is still not well understood, but it seems that tol-
capone is able to cause mitochondrial uncoupling of 
OXPOS and to disrupt the energy-producing cycle (Haasio 
et al. 2002a, b). This leads to a decreased ATP production 
and increased oxygen consumption as a compensatory 
function of the cell, and ultimately cell death may take 
place. Uncoupling of OXPOS is reflected as a rise in body 
temperature since the energy is released as heat and liver 
damage is induced due to mitochondrial toxicity (Terada 
1990).
Tolcapone has been reported to be toxic to human neu-
roblastoma cells and caused a profound reduction in ATP 
synthesis mirroring the effects of a classical uncoupler 
(Korlipara et al. 2004). However, the same study showed 
that tolcapone markedly inhibits ATP synthesis in cultured 
cells devoid of mtDNA and therefore, a functional respira-
tory chain. Tolcapone-induced hepatotoxicity could also be 
related to elevated catecholamine levels in patients which 
receive other drugs with adrenergic receptor-mediated tox-
icity (Rojo et al. 2001). The mechanism of tolcapone tox-
icity may thus also involve mechanisms independent of its 
effects on OXPHOS.
It has also been speculated that the different metabolism 
of second-generation COMT inhibitors might be respon-
sible for the toxicity observed. Metabolism of tolcapone 
into amine or acetylamine metabolites in humans can 
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be followed by oxidation to reactive oxygen species and 
induce hepatocellular injury. The same oxidative metabo-
lites are not found in humans treated with entacapone 
(Smith et al. 2003). Also, mutations in the uridine diphos-
phate-glucuronosyltransferase 1A9 gene which encodes 
for the enzyme which metabolizes tolcapone and thereby 
might promote enhanced COMT activity showed increased 
occurrence of hepatic dysfunction (Martignoni et al. 2005). 
Besides the effect on OXYPHOS, tolcapone is reportedly 
an inhibitor of BSEP transporter with comparatively higher 
value of IC50 than several more potent inhibitors of BSEP 
activity in vesicle systems (Morgan et al. 2010).
Nefazodone (mechanisms 2, 4)
Nefazodone is a triazolopyridine antidepressant withdrawn 
from the market due to the significant number of reports of 
nefazodone-mediated hepatic injury (Stewart 2002; Choi 
2003). Described clinical symptoms were jaundice and 
increases in ALT (10×), AST (10×), total bilirubin (mostly 
conjugated), and prothrombin time. Histological liver eval-
uations demonstrated centrilobular necrosis, bile-duct pro-
liferation with cholestasis (Lucena et al. 1999). The inci-
dence was reported 1 in 250,000–300,000 patients-years 
of exposure and the onset of injury varied from 6 weeks to 
8 months. Although the exact mechanism of hepatotoxicity 
remains unknown, several possible mechanisms have been 
described in the literature.
It has been shown that clinical hepatotoxicity of nefazo-
done is linked to the ability of drug to inhibit bile acid 
transport (Kostrubsky et al. 2006). Nefazodone induces a 
strong inhibition of BSEP and taurocholate efflux in human 
hepatocytes, and 1 h after oral drug administration transi-
tory increase in rat serum bile acids was observed (Kostrub-
sky et al. 2006).
Mitochondrial impairment is likely to contribute to 
nefazodone hepatotoxicity (Dykens et al. 2008). In isolated 
rat liver mitochondria and in intact HepG2 cells, nefazo-
done inhibits mitochondrial respiration. Using immunocap-
tured oxidative phosphorylation complexes, complex I, and 
to a lesser amount complex IV were identified as the targets 
of toxicity associated with accelerated glycolysis. Bioac-
tivation of nefazodone and formation of reactive interme-
diates have also been described. Nefazodone incubations 
with microsomes or recombinant CYP3A4 in the presence 
of sulphydryl nucleophiles showed formation of thiol con-
jugates of mono-hydroxylated nefazodone metabolite (Kal-
gutkar et al. 2005).
Troglitazone (mechanisms 1, 2, 3, 4)
Troglitazone was the first thiazolidinedione anti-diabetic 
drug that was removed from the market due to reported 
cases of increase in ALT and 1 in 40, 000 patients with 
reported liver failure (Faich and Moseley 2001). In clinical 
trials, 1.9 % of the subjects had elevations of ≥3× ULN of 
ALT concentrations and reported cases of overt liver injury 
and jaundice (Watkins 2005).
Formation of reactive intermediates, including quinones 
and quinone methides, is hypothesized to be responsible for 
troglitazone hepatotoxicity through either GSH depletion/
covalent binding mechanism or via oxidative stress caused 
by redox cycling of the quinone. However, there was no 
correlation of the generation of the reactive metabolites 
with susceptibility to troglitazone cytotoxicity, and chemi-
cal inhibitors of drug metabolizing enzymes in in vitro 
could not protect the cells against the toxicity (Kostrubsky 
et al. 2000; Tettey et al. 2001). Therefore, metabolic activa-
tion of troglitazone is not apparently the primary mecha-
nism of hepatotoxicity. Several other mechanisms have 
been described.
Troglitazone induces cytotoxicity in hepatocytes from 
numerous species including humans. A major non-meta-
bolic toxicity factor is via effects on mitochondria result-
ing in depletion of ATP and release of cytochrome c, 
which induces cell death via apoptosis (Tirmenstein et al. 
2002; Hu et al. 2015). Lipid peroxidation and PPARγ-
dependent steatosis are also mediated by troglitazone. 
Troglitazone induced PPARγ levels selectively in the liver 
under pathophysiological conditions, and severe steatosis 
may result in the accumulation of the drug in lipid-rich 
hepatocytes, with subsequent lipid peroxidation, and pre-
dispose the liver to the development of fibrosis (Bedoucha 
et al. 2001; Boelsterli and Bedoucha 2002). Susceptibility 
to liver injury in individuals has been attributed to explain 
the distinct sensitivity of patients to troglitazone. It has 
been shown that diabetics, obese individuals, and other 
persons with impaired liver function, were more likely 
predisposed to troglitazone toxicity due to decreased abil-
ity to eliminate the drug, compromised mitochondrial 
function in the liver cells, bile salt retention and steatosis, 
and/or underlying inflammatory status of the liver in dia-
betic subjects.
Other mechanisms linked to mechanisms of hepatotox-
icity are the inhibition of the BSEP transporter by trogl-
itazone and its metabolite, troglitazone sulphate, with the 
accumulation of toxic bile salts in the liver cells, cholesta-
sis and apoptosis through the Fas death receptor signalling 
pathway (Funk et al. 2001; Yang et al. 2014). Inhibition of 
BA transport by troglitazone and its major metabolite, tro-
glitazone sulphate, has recently been shown through use 
of Quantitative Systems Pharmacology (QSP) to predict 
delayed hepatotoxicity in humans due to hepatocellular 
accumulation of toxic bile acids and drug exposure, and 
species differences attributable to the pathophysiology of 
bile acids (Yang et al. 2014).
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Adaptive immunity (mechanism 5)
It is clear from the literature that immune responses and 
associated autoimmunity play an important role in both 
predictive (acute) and idiosyncratic DILI (Fig. 3.5). There 
is an increased weight of evidence for the role of immune 
cells (lymphocytes, macrophages, and neutrophils) in 
hepatic pathology.
Although hepatic inflammation is a common finding in 
drug-induced liver toxicity, the classic immune-allergic 
or hypersensitivity reactions are generally found in only 
a minority of DILI patients. The inflammatory phenotype 
has been attributed to the innate immune response gener-
ated by Kupffer cells, monocytes, neutrophils, and lympho-
cytes. The adaptive immune system is also influenced by 
the innate immune response leading to liver damage. Drugs 
that cause idiosyncratic DILI associated with fever, rash, a 
relatively short period of therapy before the onset of DILI 
and a rapid onset on re-challenge fit into the immune idi-
osyncrasy category.
Ximelagatran (mechanism 5)
Ximelagatran was the first oral direct thrombin inhibitor 
that reached the market for short-term use in the preven-
tion of venous thromboembolism and was assessed for the 
prevention and treatment of a range of thromboembolic 
disorders for chronic use. Pre-clinical and toxicological 
studies provided no indication of ximelagatran affecting 
hepatic functions. Also, in short-term prophylaxis, there 
was no increase in the incidence of liver enzyme elevations 
with ximelagatran. However, clinical trials with long-term 
(>35 days) treatment with ximelagatran showed increased 
rates of liver enzyme elevations (Wallentin et al. 2003; 
Schulman et al. 2003; Olsson 2003; Lee et al. 2005; Albers 
et al. 2005; Fiessinger et al. 2005). The clinical pattern of 
events suggests hepatocellular damage. The combination of 
ALT >3 ULN and total bilirubin >2 ULN was 0.5 % among 
patients treated with ximelagatran (Keisu and Andersson 
2010). Return of ALT to normal was documented in the 
majority of patients whether treatment was maintained or 
discontinued, suggesting an adaptive mechanism. Extensive 
in vitro studies at the molecular, subcellular and cellular 
level have not been able to define mechanisms explaining 
the pattern of hepatic injury observed in these long-term 
clinical trials (Kenne et al. 2008).
Previously reported mechanisms of drug-induced 
hepatotoxicity are unlikely to explain the observed ALT 
elevations in ximelagatran exposed individuals: ximela-
gatran metabolism does not involve the CYP450 system 
and does not form reactive metabolites, no effects have 
been observed below 100 µM ximelagatran when inves-
tigating cell viability, mitochondrial function, calcium 
homoeostasis, apoptosis, cytoskeleton, reactive oxygen 
species, GSH levels, bile acid transporters and nuclear 
receptors. The knock down of mARC2, the enzyme that 
reduces ximelagatran, has recently illustrated that the mito-
chondrial toxicity is strongly inhibited, suggesting a com-
ponent of metabolic activation and decrease in GSH levels 
(Neve et al. 2015).
A possible immunogenic pathogenesis, a strong genetic 
association between elevated ALT and the major histocom-
patibility complex (MHC) alleles DRB1*07 and DQA1*02 
was discovered and replicated, suggested an underlying 
immune-related mechanism but with no clinical signs of 
immunopathology (Kindmark et al. 2008).
Dabigatran etexilate is another novel direct thrombin 
inhibitor DTI proven to be effective and liver-friendly in 
various randomized controlled clinical trials mainly in the 
settings of venous thromboembolism and atrial fibrillation 
(Ma et al. 2011). Although not formally on the list of nega-
tive controls, it is used in some of the MIP-DILI experi-
ments as a comparison for ximelagatran.
Flucloxacillin (mechanism 5)
Flucloxacillin is a β-lactam antibiotic, used as the first 
line treatment for Staphylococcal infections. Common use 
of drug induced cholestatic liver injury in 8.5 in 100,000 
patients with the delayed onset of clinical symptoms 
1–45 days and 1.8 following 46–90 days after starting flu-
cloxacillin therapy (Koek et al. 1994; Dobson et al. 2005; 
Russmann et al. 2005; Li et al. 2009). The mechanism or 
mechanisms of cholestasis with bile duct injury and Vanish-
ing Bile Duct Syndrome (ductopenia) are largely unknown, 
yet small amounts of the compound form metabolites 
that involved the activity of CYP3A4, which itself may 
be under genetic control. Whether the formation of these 
metabolites is directly toxic to cholangiocytes after excre-
tion into bile or formed in cholangiocytes is not yet known. 
It is generally accepted that an immune-mediated response 
subsequently accounts for the development of the directly 
or indirectly linked genetic pre-disposition of DILI, but the 
mechanisms are still to be conclusively determined.
Strong HLA association with DILI and activation of 
CD8+ T cells isolated from patients with DILI are sugges-
tive for adaptive immune activation. HLAB*57:01 geno-
type carriers have an approximately 80-times higher risk 
(odd ratios = 80.6) of flucloxacillin-induced DILI, but not 
all carriers will develop DILI (Daly et al. 2009). Evidence 
showed that reactions to flucloxacillin are driven by drug-
specific activation of CD8+ T lymphocytes. Flucloxacillin-
responsive CD4+ and CD8+ T cells from patients with 
DILI have been characterized and shown that naive CD8+ 
T cells from volunteers expressing HLA-B*57:01 are acti-
vated with flucloxacillin (Monshi et al. 2013). Covalent 
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modification of flucloxacillin is thought to be a prerequisite 
for flucloxacillin-induced liver injury (Carey and Van Pelt 
2005). Flucloxacillin modifies specific lysine residues on 
human serum albumin (Monshi et al. 2013). However, rela-
tionship between adduct formation in liver, immune activa-
tion and liver injury not defined yet.
Flucloxacillin DILI is the only model of idiosyncratic 
immune-mediated DILI with patient data to confirm an 
immune pathogenesis.
Negative control compounds
Buspirone, entacapone, metformin and pioglitazone were 
proposed as negative controls. Some are structural ana-
logues of training compounds with less or no toxic effects 
at the therapeutic dose when compared to the matched 
positive training compound. Others are not structural ana-
logues, but do address the same pharmaceutical target with-
out evidence of known liver toxicity.
It is important to mention that probably no compound is 
a ‘true negative’ with regard to cellular toxicity and dose. 
Equally, no compound will necessarily target exclusively 
one pathway, so there will always be ‘biological back-
ground’ or multiple toxicological events, and the compen-
satory mechanisms invoked.
Buspirone
Buspirone, the azaspirodecanedione anxiolytic and antide-
pressant, is a 5-HT1A receptor partial agonist and a mixed 
agonist/antagonist on postsynaptic dopamine receptors. 
Without any reports or clinical observations associated with 
DILI, it is commonly utilized as negative control drugs 
(Wu et al. 2016).
Buspirone is a marketed structural analogue of nefazo-
done, and it is commonly used as its pair in the studies, 
together with trazodone. Inhibition of canicular transport 
with nefazodone has been reported, but not with trazodone 
or buspirone (Kostrubsky et al. 2006). Accordingly, nefazo-
done was the most toxic, trazodone had relatively modest 
effects, whereas buspirone showed the least cytotoxicity 
and effects on mitochondrial function (Dykens et al. 2008).
Although buspirone, like nefazodone, generates 
p-hydroxybuspirone in liver microsomes, no sulphydryl 
conjugates of this metabolite were observed suggesting that 
two-electron oxidation of p-hydroxybuspirone to the cor-
responding quinone-imine is less favourable. It was also 
observed that the 2-aminopyridine or 2-aminopyrimidine 
derivatives present a ‘safer’ alternative to aniline-based 
compounds, which are prone to bioactivation (Kalgutkar 
et al. 2005), and perhaps confirms the lack of idiosyncratic 
hepatotoxicity with buspirone in the clinic.
Entacapone
Entacapone is a selective, potent and reversible COMT 
inhibitor and structural analogue of tolcapone. While tol-
capone is under strict regulations on liver enzyme monitor-
ing, due to the reported cases of hepatotoxicity, entacapone 
has not been related to reported cases of associated liver inju-
ries in patients. For this reason, entacapone was selected as a 
negative training compounds used in the MIP-DILI project.
In clinical use, entacapone has only been reported to 
induce hepatotoxicity in 3 cases (Fisher et al. 2002). How-
ever, in two of these cases, the patients had concomitant 
medications with hepatotoxic potential, and the third case 
was reported with a history of long-standing alcohol abuse 
and alcohol-induced liver cirrhosis.
In vitro assays have shown that entacapone is a weak 
uncoupler of oxidative phosphorylation at high concentra-
tions, while tolcapone has been reported to be an uncou-
pler at low micro-molar concentrations (Nissinen et al. 
1997; Haasio et al. 2002a). Sets of proteins interacting 
with entacapone or tolcapone were identified in human cell 
line HepG2 and rat liver subcellular fractions. The cellu-
lar distribution of proteins captured by entacapone was not 
linked to mitochondrial function, while for tolcapone, a 
large proportion of proteins were identified to be mitochon-
drial origin (Fischer et al. 2010). Also, in in vivo studies 
in rats tolcapone were more toxic than entacapone causing 
high mortality, elevation of body temperature and necrotic 
changes in liver tissue (Haasio et al. 2001, 2012b).
Difference in toxicity could also be a result of differ-
ences in the metabolism of drugs. Amine or acetylamine 
metabolites that can be followed by oxidation to reac-
tive oxygen species and induce hepatocellular injury by 
being trapped by GSH to form metabolic adducts were not 
observed in with entacapone (Smith et al. 2003). Entaca-
pone clearance is also significantly higher than tolcapone 
clearance in humans (Data from FDA approved labelling). 
In addition, recent work has demonstrated that both drugs 
have the potential to alter hepatobiliary transport causing 
modest inhibition of the BSEP and the basolateral efflux 
transporters (MRP3 and MRP4) (Morgan et al. 2013).
Metformin
Metformin is an antihyperglycaemic agent, which improves 
glucose tolerance in patients with type 2 diabetes, lowering 
both basal and postprandial plasma glucose. Because met-
formin is not metabolized in the liver (Sirtori et al. 1978), 
it has been considered safe from a hepatic liver injury 
although known cases of cholestasis have been reported 
(Babich et al. 1998; Desilets et al. 2001; Nammour et al. 
2003; Kutoh 2005).
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Metformin can promote liver mitochondria injury and 
predispose to cell death (Carvalho et al. 2008; Bridges 
et al. 2014). Biguanide-induced mitochondrial dysfunc-
tion yields increased lactate production and cytotoxic-
ity of aerobically poised HepG2 cells and human hepato-
cytes in vitro (Dykens et al. 2008). However, human vivo 
and clinical side effects showed fewer than 10 cases of 
metformin-induced hepatotoxicity (mixed pattern) (Saadi 
et al. 2013). These cases are idiosyncratic, usually associ-
ated with alcohol or other drugs, and mainly occur in older 
patients (Kutoh 2005; Cone et al. 2010; Saadi et al. 2013).
Pioglitazone
Pioglitazone, a second-generation thiazolidinedione, is 
commonly used in the management of type 2 diabetes mel-
litus. Unlike troglitazone, pioglitazone is generally consid-
ered safe from a hepatic standpoint and is commonly used 
as negative compound for liver toxicity studies. Although 
case reports of liver injury and failure with pioglitazone 
have been published (Maeda 2001; May et al. 2002; Naga-
saka et al. 2002; Pinto and Cummings 2002; Floyd et al. 
2009), the risk of liver failure or hepatitis is not higher than 
with other oral antidiabetic agents (Rajagopalan et al. 2005; 
Berthet et al. 2011).
In vitro studies in hepatocyte cultures showed that tro-
glitazone alone among the thiazolidinediones is toxic 
(Kostrubsky et al. 2000). The difference in the profiles is 
the presence of the side chain of troglitazone, which might 
uniquely predispose it among the thiazolidinediones to 
hepatotoxicity due to the quinone metabolite formation. 
From electrochemical oxidations of pioglitazone in the 
presence of GSH, no GSH conjugates could be identified 
(Madsen et al. 2008a).
Moreover, the observed ALT elevation levels in troglita-
zone clinical trials, results of studies in hepatocyte cultures 
and evidence of the distinct metabolic pathway suggest that 
hepatotoxicity may not be a class effect of the thiazolidin-
ediones but rather a unique effect of troglitazone and that 
pioglitazone do not share its hepatotoxic profile (Scheen 
2001; Tolman and Chandramouli 2003).
Summary and conclusions
Training compounds were selected on the basis of clinical 
evidence of DILI and availability of known mechanisms 
by which these compounds are believed to cause liver 
injury. The evidence-based selection of the set of training 
compounds was subsequently employed systematically 
for the pharmacological, physiological and toxicological 
evaluation of model systems to support the translational 
relevance of these models and improvement of a greater 
understanding of drug liability’s mechanisms to cause DILI 
in man. From a total of 40 compounds nominated, 10 train-
ing compounds and 4 negative controls were selected.
It is acknowledged at the outset in the selection of 
drug compounds that our present knowledge of the mech-
anisms by which drugs are known to cause human DILI 
remains incomplete. Moreover, through the evidence-
based selection of training compounds, many can be 
regarded as largely imperfect ‘reagents’ to probe, in iso-
lation and selectively, each of the 5 categories of DILI, 
where many of the drugs reviewed herein neither exhibit 
a specific biochemical or toxicological target. As such, 
many if not all drugs in this review appear to exhibit 
multiple toxicological mechanisms when evaluated 
in model systems or clinical intelligence (see Fig. 3). 
Thus it is clear that prediction of DILI in man requires a 
matrix of multiple test systems and training compounds 
to afford a deeper understanding of which mechanisms/
liabilities are relevant to man. The ‘selection’ of train-
ing compounds therefore offers a valuable tool to profile 
DILI mechanisms and to interrogate existing and novel 
in vitro systems for the prediction of human DILI. This a 
priori knowledge of drugs to target more than one mech-
anism leading to probable DILI also underlies the basis 
for a more rational integrated approach to the investiga-
tion of DILI early in drug discovery to eliminate simple 
and more complex liabilities through the use of a tiered 
approach to early safely risk assessment.
Several publications have recently appeared in which 
the here selected training compounds and negative controls 
have been investigated in order to substantiate their utility 
as training compounds to profile and elucidate further DILI 
mechanisms and to interrogate existing and novel in vitro 
systems for the prediction of human DILI (Sison-Young 
et al. 2015; Bell et al. 2016; Sison-Young et al. 2016; den 
Braver-Sewradj et al. 2016; den Braver et al. 2016).
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